Please login to the form below

Not currently logged in
Email:
Password:

Ex-BMS exec jumps to Gilead to lead research group

Gilead appoints Michael Quigley to lead research team

A former Bristol-Myers Squibb executive has jumped ship to Gilead, where he will head up the company’s research biology group.

Michael QuigleyMichael Quigley (pictured left) joins Gilead from BMS, where he most recently served as vice president and head of the company’s Tumour Microenvironment Modulation Thematic Research Center and site head of the Redwood City, California location.

At BMS, Quigley held responsibility for setting the strategy for the company’s oncology discovery portfolio and business development activities. He also oversaw target identification, validation and preclinical development of large and small molecule therapies.

Gilead has also simultaneously announced the promotion of Linda Higgins, who has recently taken on the role of senior vice president and head of external innovation.

Linda HigginsHiggins (pictured right) joined Gilead in 2010 to lead an expansion of the company’s biology organisation. That included the expansion of the company’s biologics and biomarker functions, as well as the addition of inflammation, oncology and immunology discovery groups.

Under her leadership, Gilead’s biology organisation supported the discovery and development of eight marketed products and the development of more than 30 compounds into development.

“We are very pleased to welcome Mike to Gilead and Linda to her new role, as we seek to build and scale our access to scientific innovation, both internally and externally,” commented William Lee. “These appointments strengthen our research discovery organisation and will help position us to reach our ambitious goal of bringing 10 new transformative therapies to patients over the next 10 years.”

Article by
Lucy Parsons

21st February 2020

From: Research

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Hanson Zandi

Hanson Zandi is a Creative and Digital Healthcare Agency. We combine 30 years’ experience with the enthusiasm of a start-up...

Latest intelligence

DEMAND DIVERSITY REPORT 02: Why is the LGBTQ+ community facing poorer health outcomes due to COVID-19?
We’re all aware that clinical trials have been discussed more widely since the COVID-19 pandemic. While that’s a great thing for raising awareness of clinical trials in general, it’s also...
CHECKLIST 04: Let’s make your patient recruitment strategies a success
From how to generate insights to define your audience to drilling down those all-important key messages, our checklist has everything you need to think of, covered....
Multichannel engagement and the need for greater understanding of European markets
By Laurence Olding and Georgina James...

Infographics